Lenvatinib Plus Pembrolizumab Maintains Survival Benefit in Advanced RCC
June 5th 2023Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
Read More
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI
June 3rd 2023Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
Read More
Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer
May 2nd 2023Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.
Read More
Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC
April 29th 2023A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
Read More
Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC
June 7th 2022Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.
Read More
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
June 4th 2022Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
Read More
Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma
May 16th 2022Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.
Read More
TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS
June 8th 2021The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Read More
Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans
May 19th 2021An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.
Read More
Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations
April 13th 2021Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.
Read More
PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV
February 13th 2021February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.
Read More
Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC
February 11th 2021February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.
Read More
FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC
May 20th 2020The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.
Read More
TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC
March 12th 2020The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.
Read More
Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial
March 12th 2020Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
Read More